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to develop skin malignancy even after prolonged time of observation.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Many skin diseases like xeroderma pigmentosum and nevoid
basal cell carcinoma syndrome are genetically liable for
recurrent solar keratosis and skin malignancies like basal cell
carcinoma (BCC), squamous cell carcinoma (SCC) and
malignant melanoma ( vanSteeg and Kraemer, 1999; Manfredi
et al., 2004).
Ultraviolet radiation (UVR) is a complete carcinogen
(Dumaz et al., 1997). Many in vitro and in vivo animal studies
have investigated the modulations induced in the human sys-ntiﬁc Council of Dermatology
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lseviertem by UV, outlining changes in the activities of natural killer
cells and T cells and in cytokine regulation (Yoshikawa et al.,
1990). UV immunosuppression may interfere with prolifera-
tion and functioning of langerhans (LGs) cells and may also
induced LG apoptosis (Weitzen and Bonavida, 1984). The
molecular changes induced by UV generate multiple conse-
quent or concomitant mechanisms: DNA damage, depletion
of some protective cytokines such as IL-1, IL-2 and INF-c,
or the increase of tumor necrosis factor-a, IL-6, IL10 and
IL-15, resulting in the immunosuppressed skin milieu that
permits and maintains the proliferation of mutated cellular
clones (Duthie et al., 1999).
Modern molecular-based research has revealed that the
Signal transducer and activator of transcription 3 (Stat3), a
cytoplasmic transcription factor, is constitutively activated in
various types of cancer including skin cancer. Inhibition of
activated Stat3 leads to decreased proliferation and apoptosis
of many cancer-derived cell lines (Pedranzini et al., 2004; Lem-
bo et al., 2008).
Big and multiple malignancy might need excision and graft-
ing. In the last 30 years, I have the opportunity of seeing
patients with multiple face skin malignancy that treated by
skin grafting but no new lesions or recurrence appeared on
the recipient grafted area after watching for long time even
up to 20 years.
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sporadic cases of skin grafting with new malignancy arising
in grafted recipient area but there are a lot of controversy
whether these new malignancies arising from the graft or from
original remaining recipient skin (Martin et al., 2005; Karri
et al., 2005; Lemierre et al., 2007; Blackwell and McComb,
1969; Selma et al., 2002; Akizuki and Harii, 1990).
The aim of the present paper is to report a case of geneti-
cally susceptible for multiple skin malignancies that needed
excision of skin and grafting but no recurrence or the appear-
ance of skin related malignancy like solar keratosis, BCC, SCC
or malignant melanoma in the grafted recipient sites.
2. Case report
A 65 years old man who has pigmented xerdermoid presented
with multiple and recurrent skin malignancy on his light-dam-
aged skin since early life. During the course of his illness, he
has developed a frequent and multiple solar keratosis and
squamous cell carcinoma. Positive family history of the similar
disease was seen in his son. Excisions and grafting have been
carried out for big cancers since 1982 but he has never
developed any solar damage or skin malignancy in the graft
recipient areas.
On physical examination marked photo damage of the sun
exposed skin especially face and hands with multiple small tu-
mors of different size and shape on his face that clinically
looked SCC. Some of them were arising from original skin that
was closely adjacent to the margin of the two grafted areas.
There were two grafted areas, each on either side of his face.Figure 1 Skin graft since 1982.
Figure 2 Father and son.The grafts looked apparently healthy as no solar keratosis,
BCC, SCC were observed (Figs. 1 and 2).3. Discussion
There are many syndromes like xeroderma pigmentosum and
epiderodysplasia verruciform, which are susceptible for skin
malignancy. Although might have different etiologies but these
malignancies usually arise on the face and could be on other
sun exposed sites and rarely elsewhere. The question to be
raised, why mainly on the face? Are the skin cells are geneti-
cally have more tendency to develop skin cancer and more lia-
ble to UV damage than the skin elsewhere, or the sun damage
is the most important triggering factor and especially during
early childhood sun exposure is more important than later
on but the thing that against this thought, is that bald men
developing solar keratosis or malignancy on the bald skin
although the balded scalp skin was exposed to sun after their
thirties years of age. But why not on the dorsa of hands, neck
and other sun exposed area. It is most probably that the skin
has great regional variation regarding the thickness of the skin,
the defensive mechanism, cytokines, ﬁbronectin and gene
expression like P53 (IGISU, 1987; Offringa et al., 2008; Pon-
teAˆn et al., 1997). So each part of the skin has its own biolog-
ical function and behavior (Thomas et al., 1984). The
suggested possibility is that when donor skin is grafted on
new recipient area, might change its behavior regarding all
its biological features required for the development of skin
cancer. Accordingly might develop more defensive mechanism
against UVL changes and skin tumors although it’s now sun
exposed. This thought is supported by full thickness graft,
which when transferred to the face did not develop sun damage
and rarely develop malignancy although long time has passed
since grafting up to 20 years. Also autologous grafting of bcc
from one region into another site on the same patient caused
regression of these tumors while the remainder of the grafted
skin survived and grew normally (Blackwell and McComb,
1969). There are few case reports recording malignancy on
the graft but all are controversial for the following reasons;
either the graft is split and the damaged skin is not completely
excised, so the remaining skin appendages like hair and sweat
glands might be responsible for the new recurrent tumors. In
others the original BCC or SCC was not completely eradicated
before grafting, or the graft was transferred to sun covered
area like thigh and developed skin cancer coincidental. So
the new tumor on the graft is not related to grafting (Martin
et al., 2005; Lemierre et al., 2007; Selma et al., 2002). It’s well
known that UV radiation of the skin causes, reduced and
clearance of langerhans cells but we could have subtype of lan-
gerhans cells that resist UVR effect, hence can confer protec-
tion against new skin cancer. This observation has been well
documented in patients with polymorphic light eruption
(PLE) where the prevalence of PLE in people with SC was
7.5%, compared with 21.4% for controls (Lembo et al., 2008).
From these observations and the recorded literatures, we can
speculate the following reasons behind why grafted skin does
not develop skin malignancy: the grafted skin change its biolog-
ical and immunological status, these could be subtype of langer-
hans cells in the grafted skin that resist skin malignancy, the P53
protein might be more efﬁcient in protection against cancer or
the Stat3 could be reduced in the grafted skin.
Is the skin graft immune against new malignancy? 754. Conclusion
The newly grafted skin in patients with genetically susceptible
for skin cancer like XD could be immune against new cancers.
So immunological and biological study of the grafted skin
including the langerhans cell, P53 and Stat3 is strongly
recommended.
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